U.S. Markets open in 2 hrs 40 mins

Free Technical Research on Evolus and Three More Generic Drugs Equities

Stock Research Monitor: FCSC, FLXN, and MNTA

LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on EOLS sign up now at www.wallstequities.com/registration. On Tuesday, July 24, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.79% and 0.48% higher, respectively at the closing bell, while the NASDAQ Composite stayed bearish, finishing marginally lower by 0.01%. US markets sawsevenout of nine sectors finishing the day ingreen and two in red. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drugs - Generic equities this morning: Evolus Inc. (EOLS), Fibrocell Science Inc. (NASDAQ: FCSC), Flexion Therapeutics, Inc. (NASDAQ: FLXN), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Evolus

On Tuesday, shares in Irvine, California headquartered Evolus Inc. recorded a trading volume of 623,008 shares, which was higher than their three months average volume of 549.00 thousand shares. The stock ended at $19.53, declining 2.79% from the last trading session. The Company's shares have gained 153.31% over the previous three months. The stock is trading above its 200-day moving average by 16.95%. Furthermore, shares of Evolus, which provides medical aesthetic products for physicians and their patients in the US, have a Relative Strength Index (RSI) of 36.32. Get the full research report on EOLS for free by clicking below at:

www.wallstequities.com/registration/?symbol=EOLS

Fibrocell Science

Exton, Pennsylvania-based Fibrocell Science Inc.'s stock finished yesterday's session 4.44% lower at $2.15. A total volume of 284, shares was traded. The stock is trading below its 50-day moving average by 20.95%. Furthermore, shares of Fibrocell Science, which focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the US, have an RSI of 33.65. Get access to our top-rated research, including the free report on FCSC at:

www.wallstequities.com/registration/?symbol=FCSC

Flexion Therapeutics

At the close of trading on Tuesday, shares in Burlington, Massachusetts headquartered Flexion Therapeutics, Inc. saw a drop of 0.37%, ending the day at $27.12. The stock recorded a trading volume of 232,088 shares. The Company's shares have advanced 10.69% in the previous three months and 10.65% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 1.59% and 8.19%, respectively. Moreover, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have an RSI of 54.70.

On June 28th, 2018, research firm The Benchmark Company initiated a 'Buy' rating on the Company's stock, with a target price of $39 per share. Click here to subscribe for a free membership which welcomes you with our report on FLXN at:

www.wallstequities.com/registration/?symbol=FLXN

Momenta Pharmaceuticals

Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s shares ended the day 0.98% higher at $30.80 with a total trading volume of 381,348 shares. The stock has gained 43.59% in the last month, 57.54% in the previous three months, and 83.33% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 29.89% and 72.04%, respectively. Additionally, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 81.61. To get free access to your research report on MNTA, sign up at:

www.wallstequities.com/registration/?symbol=MNTA

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities